vs
Fulgent Genetics, Inc.（FLGT）与万物新生（RERE）财务数据对比。点击上方公司名可切换其他公司
Fulgent Genetics, Inc.的季度营收约是万物新生的1.9倍（$83.3M vs $43.2M），万物新生净利率更高（16.9% vs -28.1%，领先45.0%）
Fulgent Genetics是一家分子诊断技术企业，开发并提供覆盖携带者筛查、肿瘤基因检测、传染病检测、遗传性疾病分析的多元基因检测服务，主要客户为北美地区的医疗机构、药企、科研院所及公共卫生组织。
万物新生集团（ATRenew Inc.）是中国领先的二手消费电子产品交易与服务平台运营商，核心业务覆盖数码产品回收、质检、翻新及售卖，运营有爱回收等知名品牌，服务覆盖个人消费者及企业客户，市场遍及国内及部分东南亚地区。
FLGT vs RERE — 直观对比
营收规模更大
FLGT
是对方的1.9倍
$43.2M
净利率更高
RERE
高出45.0%
-28.1%
损益表 — Q4 FY2025 vs Q1 FY2023
| 指标 | | |
|---|---|---|
| 营收 | $83.3M | $43.2M |
| 净利润 | $-23.4M | $7.3M |
| 毛利率 | 39.1% | — |
| 营业利润率 | -43.5% | — |
| 净利率 | -28.1% | 16.9% |
| 营收同比 | 9.3% | — |
| 净利润同比 | -297.7% | — |
| 每股收益（稀释后） | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FLGTRERE
| Q4 25 | $83.3M | — | ||
| Q3 25 | $84.1M | — | ||
| Q2 25 | $81.8M | — | ||
| Q1 25 | $73.5M | — | ||
| Q4 24 | $76.2M | — | ||
| Q3 24 | $71.7M | — | ||
| Q2 24 | $71.0M | — | ||
| Q1 24 | $64.5M | — |
净利润FLGTRERE
| Q4 25 | $-23.4M | — | ||
| Q3 25 | $-6.6M | — | ||
| Q2 25 | $-19.0M | — | ||
| Q1 25 | $-11.5M | — | ||
| Q4 24 | $-5.9M | — | ||
| Q3 24 | $-14.6M | — | ||
| Q2 24 | $-8.7M | — | ||
| Q1 24 | $-13.5M | — |
毛利率FLGTRERE
| Q4 25 | 39.1% | — | ||
| Q3 25 | 42.2% | — | ||
| Q2 25 | 42.1% | — | ||
| Q1 25 | 38.6% | — | ||
| Q4 24 | 41.8% | — | ||
| Q3 24 | 37.3% | — | ||
| Q2 24 | 37.3% | — | ||
| Q1 24 | 34.3% | — |
营业利润率FLGTRERE
| Q4 25 | -43.5% | — | ||
| Q3 25 | -18.3% | — | ||
| Q2 25 | -24.1% | — | ||
| Q1 25 | -26.9% | — | ||
| Q4 24 | -21.2% | — | ||
| Q3 24 | -23.8% | — | ||
| Q2 24 | -26.6% | — | ||
| Q1 24 | -33.8% | — |
净利率FLGTRERE
| Q4 25 | -28.1% | — | ||
| Q3 25 | -7.9% | — | ||
| Q2 25 | -23.2% | — | ||
| Q1 25 | -15.7% | — | ||
| Q4 24 | -7.7% | — | ||
| Q3 24 | -20.4% | — | ||
| Q2 24 | -12.3% | — | ||
| Q1 24 | -20.9% | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $50.2M | $228.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.1B | $557.1M |
| 总资产 | $1.2B | $722.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FLGTRERE
| Q4 25 | $50.2M | — | ||
| Q3 25 | $117.6M | — | ||
| Q2 25 | $87.9M | — | ||
| Q1 25 | $67.3M | — | ||
| Q4 24 | $55.1M | — | ||
| Q3 24 | $58.0M | — | ||
| Q2 24 | $65.1M | — | ||
| Q1 24 | $54.7M | — |
股东权益FLGTRERE
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — |
总资产FLGTRERE
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $1.2B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-78.1M | — |
| 自由现金流经营现金流 - 资本支出 | $-83.1M | — |
| 自由现金流率自由现金流/营收 | -99.7% | — |
| 资本支出强度资本支出/营收 | 6.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-124.2M | — |
8季度趋势，按日历期对齐
经营现金流FLGTRERE
| Q4 25 | $-78.1M | — | ||
| Q3 25 | $11.1M | — | ||
| Q2 25 | $-30.2M | — | ||
| Q1 25 | $-4.4M | — | ||
| Q4 24 | $25.0M | — | ||
| Q3 24 | $-15.5M | — | ||
| Q2 24 | $4.3M | — | ||
| Q1 24 | $7.3M | — |
自由现金流FLGTRERE
| Q4 25 | $-83.1M | — | ||
| Q3 25 | $5.1M | — | ||
| Q2 25 | $-37.0M | — | ||
| Q1 25 | $-9.1M | — | ||
| Q4 24 | $21.2M | — | ||
| Q3 24 | $-35.0M | — | ||
| Q2 24 | $-8.7M | — | ||
| Q1 24 | $3.2M | — |
自由现金流率FLGTRERE
| Q4 25 | -99.7% | — | ||
| Q3 25 | 6.0% | — | ||
| Q2 25 | -45.2% | — | ||
| Q1 25 | -12.5% | — | ||
| Q4 24 | 27.9% | — | ||
| Q3 24 | -48.8% | — | ||
| Q2 24 | -12.2% | — | ||
| Q1 24 | 5.0% | — |
资本支出强度FLGTRERE
| Q4 25 | 6.0% | — | ||
| Q3 25 | 7.2% | — | ||
| Q2 25 | 8.3% | — | ||
| Q1 25 | 6.4% | — | ||
| Q4 24 | 5.0% | — | ||
| Q3 24 | 27.2% | — | ||
| Q2 24 | 18.2% | — | ||
| Q1 24 | 6.3% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FLGT
| Precision Diagnostics | $48.3M | 58% |
| Anatomic Pathology | $27.0M | 32% |
| Biopharma Services | $7.8M | 9% |
RERE
暂无分部数据
